

# ASX Release

---

## SUDA LTD: APPENDIX 4C FOR FOURTH QUARTER FY2016

**PERTH, AUSTRALIA – 29 July 2016:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the fourth quarter of FY2016. Receipts from customers for the period were \$1.5 million, an increase of 12% from the fourth quarter of FY2015.

The net operating cash loss for the fourth quarter was \$1.0 million, compared to \$0.7 million in the same period of the previous year. The increase in cash outflow in the quarter included an adjustment for research relating to SUDA's new-generation optimised SUD-003 sildenafil oro-mucosal spray for erectile dysfunction. There was also an increase in payments for other working capital. The cash position as at 30 June 2016 was \$2.4 million.

SUDA's CEO, Mr Stephen Carter, commented: "Our negotiations with pharmaceutical companies to license SUDA's first-in-class oro-mucosal sprays continue to advance towards final agreements. These discussions span various products and territories. We have overcome several product-related challenges that have slowed the pace of licensing discussions. With these matters addressed, we are well placed to finalise multiple commercial agreements. In addition, our medical and surgical supplies subsidiary, Westcoast, continues to perform well with receipts from customers up 12% from the fourth quarter in the previous year."



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

## NOTES TO EDITORS:

### About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes Zolpimist®, a first-in-class oral spray of zolpidem for insomnia. Zolpimist® is marketed in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

**SUDA LTD**

ABN

35 090 987 250

Quarter ended ("current quarter")

30 June 2016

### Consolidated statement of cash flows

		Current quarter	Year to date
		\$A'000	12 Months \$A'000
<b>Cash flows related to operating activities</b>			
1.1	Receipts from customers	1,526	5,836
1.2	Payments for (a) staff costs	(383)	(1,725)
	(b) advertising and marketing	-	-
	(c) research and development	(140)	(140)
	(d) leased assets	(6)	(15)
	(e) other working capital	(1,990)	(6,406)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	28	110
1.5	Interest and other costs of finance paid	(30)	(207)
1.6	Income taxes paid	-	-
1.7	Other (R&D Tax Incentive and EMDG)	35	744
<b>Net operating cash flows</b>		<b>(960)</b>	<b>(1,803)</b>

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date 12 Months \$A'000
1.8 Net operating cash flows (carried forward)	<b>(960)</b>	<b>(1,803)</b>
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	(647)
(c) intellectual property	(158)	(1,394)
(d) physical non-current assets	(2)	(57)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	15	29
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
<b>Net investing cash flows</b>	<b>(145)</b>	<b>(2,069)</b>
<b>1.14 Total operating and investing cash flows</b>	<b>(1,105)</b>	<b>(3,872)</b>
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	1,025
1.18 Repayment of borrowings	-	(920)
1.19 Dividends paid	-	-
1.20 Other (capital raising fees)	-	(36)
<b>Net financing cash flows</b>	<b>-</b>	<b>69</b>
<b>Net increase (decrease) in cash held</b>	<b>(1,105)</b>	<b>(3,803)</b>
1.21 Cash at beginning of quarter/year to date	3,554	6,252
1.22 Exchange rate adjustments to item 1.20	-	-
<b>1.23 Cash at end of quarter</b>	<b>2,449</b>	<b>2,449</b>

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	148
1.25	Aggregate amount of loans to the parties included in item 1.11	Nil
1.26	Explanation necessary for an understanding of the transactions	
	Payment of Salary and Directors' Fees for the quarter ended 30 <sup>th</sup> June 2016	

**Non-cash financing and investing activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A
-----

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A
-----

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

### Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	499	504
4.2	Deposits at call	1,950	3,050
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)		2,449	3,554

### Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	N/A
5.2	Place of incorporation or registration	N/A
5.3	Consideration for acquisition or disposal	N/A
5.4	Total net assets	N/A
5.5	Nature of business	N/A

### Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here:

Date: 29 July 2016

Print name:

Managing Director  
Stephen Carter

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
  - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
  - 9.2 - itemised disclosure relating to acquisitions
  - 9.4 - itemised disclosure relating to disposals
  - 12.1(a) - policy for classification of cash items
  - 12.3 - disclosure of restrictions on use of cash
  - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.